August 28, 2015 An emerging optogenetic therapy that holds promise for restoring vision for people completely blind from retinitis pigmentosa (RP), and potentially other retinal diseases, will soon be moving into a clinical trial. RetroSense Therapeutics, developer of the treatment, has received authorization from the U.S. Food and Drug Administration (FDA) to launch the 15-person, […]

Leer Más "RETROSENSE TO LAUNCH CLINICAL TRIAL OF VISION RESTORING OPTOGENETIC THERAPY"